Echinocandin antifungal drugs (Q29398696)

Europe PubMed Central

title

Echinocandin antifungal drugs (English)

1 reference

https://doi.org/10.1016%2FS0140-6736%2803%2914472-8

14 April 2017

1 reference

Europe PubMed Central

PubMed publication ID

14550704

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14550704

20 March 2024

David W Denning

1

0 references

language of work or name

English

0 references

publication date

October 2003

1 reference

https://doi.org/10.1016%2FS0140-6736%2803%2914472-8

14 April 2017

4 October 2003

1 reference

National Center for Biotechnology Information

PubMed publication ID

14550704

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14550704

20 March 2024

number of pages

10

1 reference

full work available at URL

inferred from page(s)

https://api.elsevier.com/content/article/PII:S0140673603144728?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(03)14472-8

https://api.elsevier.com/content/article/PII:S0140673603144728?httpAccept=text/plain

20 March 2024

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(03)14472-8

20 March 2024

1 reference

https://doi.org/10.1016%2FS0140-6736%2803%2914472-8

14 April 2017

volume

362

1 reference

https://doi.org/10.1016%2FS0140-6736%2803%2914472-8

14 April 2017

issue

9390

1 reference

https://doi.org/10.1016%2FS0140-6736%2803%2914472-8

14 April 2017

page(s)

1142-1151

1 reference

https://doi.org/10.1016%2FS0140-6736%2803%2914472-8

Trends in the postmortem epidemiology of invasive fungal infections at a university hospital

14 April 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Postmortem analysis of invasive aspergillosis in a tertiary care hospital

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Survival and prognostic factors of invasive aspergillosis after allogeneic bone marrow transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Natural history of opportunistic disease in an HIV-infected urban clinical cohort

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Disseminated Penicillium marneffei infection in southeast Asia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Antifungal drug resistance in Aspergillus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Resistance of Candida species to antifungal agents: molecular mechanisms and clinical consequences

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Metabolites of microorganisms. 143. Echinocandin B, a novel polypeptide-antibiotic from Aspergillus nidulans var. echinulatus: isolation and structural components

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Pneumocandins from Zalerion arboricola. II. Modification of product spectrum by mutation and medium manipulation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

WF11899A, B and C, novel antifungal lipopeptides. I. Taxonomy, fermentation, isolation and physico-chemical properties.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Glucan synthase inhibitors as antifungal agents

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Arundifungin, a novel antifungal compound produced by fungi: biological activity and taxonomy of the producing organisms.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Arborcandins A, B, C, D, E and F, novel 1,3-beta-glucan synthase inhibitors: production and biological activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

The discovery of enfumafungin, a novel antifungal compound produced by an endophytic Hormonema species biological activity and taxonomy of the producing organisms

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Fungal ß(1,3)-D-glucan synthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Molecular organization of the cell wall of Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Aspergillus fumigatus cell wall: composition and biosynthesis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Calcineurin-dependent growth of an FK506- and CsA-hypersensitive mutant of Saccharomyces cerevisiae.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-beta-D-glucan synthase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Glucan synthase complex of Aspergillus fumigatus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Cell wall assembly by Pneumocystis carinii. Evidence for a unique gsc-1 subunit mediating beta -1,3-glucan deposition

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Differential expression and function of two homologous subunits of yeast 1,3-beta-D-glucan synthase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

The yeast cell-wall salvage pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Potent synergism of the combination of fluconazole and cyclosporine in Candida albicans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

International surveillance of blood stream infections due to Candida species in the European SENTRY Program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

In vitro antifungal activity of FK463, a new water-soluble echinocandin-like lipopeptide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

In vitro activities of a new lipopeptide antifungal agent, FK463, against a variety of clinically important fungi

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Treatment of murine disseminated candidiasis with L-743,872

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of disseminated candidiasis and aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Efficacy of FK463, a (1,3)-beta-D-glucan synthase inhibitor, in disseminated azole-resistant candida albicans infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Treatment of murine Candida krusei or Candida glabrata infection with L-743,872

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Efficacies of fluconazole, caspofungin, and amphotericin B in Candida glabrata-infected p47phox-/- knockout mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

In vitro activity of the echinocandin antifungal agent LY303,366 in comparison with itraconazole and amphotericin B against Aspergillus spp.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Comparison of In vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Influence of human sera on the in vitro activity of the echinocandin caspofungin (MK-0991) against Aspergillus fumigatus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Synergy, pharmacodynamics, and time-sequenced ultrastructural changes of the interaction between nikkomycin Z and the echinocandin FK463 against Aspergillus fumigatus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Activity of micafungin (FK463) against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Efficacy of FK463, a new lipopeptide antifungal agent, in mouse models of pulmonary aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Efficacy of caspofungin alone and in combination with voriconazole in a Guinea pig model of invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Prophylactic effect of FK463, a novel antifungal lipopeptide, against Pneumocystis carinii infection in mice

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Comparison of caspofungin and amphotericin B for invasive candidiasis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

A randomized, double-blind, double-dummy, multicenter trial of voriconazole and fluconazole in the treatment of esophageal candidiasis in immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Canadian Candidemia Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. Candidemia Study Group and the National Institute

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

NIAID Mycoses Study Group Multicenter Trial of Oral Itraconazole Therapy for Invasive Aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Refractory Aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2803%2914472-8

7 January 2021

In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species

series ordinal

52

1 reference

https://api.crossref.org/works/10.1016/S0140-6736(03)14472-8

20 March 2024

Identifiers

2 references

https://doi.org/10.1016%2FS0140-6736%2803%2914472-8

14 April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

PubMed publication ID

14550704

1 reference

Consolidated OpenCitations Corpus – April 2017